Back to News
Press Release September 12, 2019

NEWS & EVENTS

News Image

Paris, September 12th. 2019.Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes,announced today a €39 million Series B financing led by Morningside Ventures, joined byInvus with participation from existing investors Andera Partners, Sofinnova Partners and BiomedInvest.

Read full article – PDF


Read full article